Home › Data for KEYTRUDA (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium
 

Keywords :   


Data for KEYTRUDA (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium

2016-01-19 16:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Seven Registration-Enabling Trials Evaluating KEYTRUDA in Patients with Gastrointestinal Cancers are Planned or Underway KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new and updated findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in multiple gastrointestinal cancers will be presented at this years Gastrointestinal (GI) Cancers Symposium in San Francisco, Jan. 21 23. Updates on pembrolizumab include data on advanced esophageal carcinoma and new preliminary Phase 2 safety data in gastric cancer. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data range presented symposium

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.11Subtropical Storm Patty Graphics
02.11Subtropical Storm Patty Forecast Discussion Number 1
02.11Subtropical Storm Patty Wind Speed Probabilities Number 1
02.11Subtropical Storm Patty Forecast Advisory Number 1
02.11Subtropical Storm Patty Public Advisory Number 1
02.11Summary for Subtropical Storm Patty (AT2/AL172024)
02.11Tropical Storm Lane Graphics
02.11Tropical Storm Lane Forecast Discussion Number 3
More »